Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Best Practices for Successful Outcomes in Patients with Heart Failure
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a frequently misdiagnosed disease marked by significant morbidity and mortality, with a prevalence higher than anticipated in patients with heart failure (HF). In this program, experts in cardiac amyloidosis will discuss best practices for identifying HF patients for screening for ATTR-CM, explain screening and diagnostic approaches, and describe current and emerging treatments for ATTR-CM.
Ahmad Masri, MD, MS
Brett Sperry, MD
Jointly provided by the HFSA and Voxmedia and supported through an independent educational grant from AstraZeneca.